Ruetten, Hartmut

Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models

Allesøe, R. L., Lundgaard, A. T., Hernández Medina, R., Aguayo-Orozco, A., Johansen, J., Nissen, J. N., Brorsson, C., Mazzoni, G., Niu, L., Biel, J. H., et al. (2023) · Nature Biotechnology

Bioinformatics and Genomic NetworksComputational Drug Discovery Methods

Cited by 111

Predicting and elucidating the etiology of fatty liver disease: a machine learning modeling and validation study in the IMI DIRECT cohorts

Atabaki-Pasdar, N., Ohlsson, M., Viñuela, A., Frau, F., Pomares-Millan, H., Haid, M., Jones, A. G., Thomas, E. L., Koivula, R. W., Kurbasic, A., et al. (2020) · PLOS Medicine

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 97

Tolerability, safety, and pharmacokinetics of the novel cathepsin A inhibitor SAR164653 in healthy subjects

Tillner, J., Lehmann, A., Paehler, T., Lukacs, Z., Ruf, S., Sadowski, T., Pinquier, J., & Ruetten, H. (2016) · Clinical Pharmacology in Drug Development

Heart Failure Treatment and ManagementPharmacogenetics and Drug Metabolism

Cited by 14